# Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

> **NCT00310388** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 376 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Retigabine (INN), Ezogabine (USAN)

## Key facts

- **NCT ID:** NCT00310388
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07-05
- **Primary completion:** 2017-04-18
- **Final completion:** 2018-05-24
- **Target enrollment:** 376 (ACTUAL)
- **Why stopped:** No longer any benefit in collecting data since retigabine has been withdrawn from market.
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310388, "Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00310388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*